← Stephen B. Heitner

Papers by Stephen B. Heitner

Page 1 · newest first

1. Safety and Efficacy of Omecamtiv Mecarbil by QRS Duration and Cardiac Resynchronization Therapy in GALACTIC-HFJACC Heart Failure · 2026
2. Left Ventricular Ejection Fraction Reductions During Long-Term Aficamten Treatment in Obstructive Hypertrophic Cardiomyopathy: Findings From FOREST-HCMJournal of Cardiac Failure · 2026
3. Aficamten is associated with improvements in cardiac mechanics in obstructive hypertrophic cardiomyopathy: Results from FOREST-HCMProgress in Cardiovascular Diseases · 2026
4. A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEFClinical Pharmacokinetics · 2026
5. Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic CardiomyopathyCirculation · 2026
6. Aficamten for Symptomatic Nonobstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2026
7. Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCMCirculation · 2026
8. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
9. Aficamten in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
10. Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic‐Cardiodynamic Modeling to Support Safety and EfficacyCPT Pharmacometrics & Systems Pharmacology · 2026
11. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM RegistryJournal of the American College of Cardiology · 2019
12. 26-a-11653-Acc Aficamten Versus Metoprolol in Patients With Hypertension and Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2026
13. 26-a-16519-Acc Electrocardiographic Changes and Associations With Echocardiographic Changes in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the Sequoia-HCM TrialJournal of the American College of Cardiology · 2026
14. Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trialEuropean Journal of Heart Failure · 2026
15. Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMCirculation Heart Failure · 2025
16. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMCirculation Heart Failure · 2025
17. Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCMJournal of Cardiac Failure · 2025
18. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialCirculation · 2025
19. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2025
20. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialEuropean Heart Journal · 2025
21. Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
22. Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic ModelingCPT Pharmacometrics & Systems Pharmacology · 2025
23. Aficamten Treatment for Symptomatic Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2025
24. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialEuropean Heart Journal · 2025
25. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2025
26. Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy ParticipantsClinical and Translational Science · 2025
27. Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of AficamtenClinical Pharmacokinetics · 2025
28. Aficamten vs Metoprolol for Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2025
29. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCMJournal of the American College of Cardiology · 2024
30. Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysisEuropean Heart Journal · 2024
31. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
32. Aficamten and Cardiopulmonary Exercise Test PerformanceJAMA Cardiology · 2024
33. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
34. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trialEuropean Heart Journal · 2024
35. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
36. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
37. Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathyBMJ Open · 2024
38. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCMJournal of the American Heart Association · 2024
39. Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCMEuropean Journal of Heart Failure · 2024
40. Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2024
41. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Journal of Cardiac Failure · 2024
42. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid CardiomyopathyJournal of Cardiac Failure · 2023
43. Exercise Capacity in Patients With Obstructive Hypertrophic CardiomyopathyENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2023
44. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFJournal of Cardiac Failure · 2023
45. Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3Journal of Cardiac Failure · 2023
46. Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection FractionJournal of the American Heart Association · 2023
47. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection FractionENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2023
48. Efficacy of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide Level: Insights from the GALACTIC-HF TrialEuropean Journal of Heart Failure · 2023
49. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2023
50. Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathyCardiovascular Ultrasound · 2022